Evogene Ltd. (EVGN)
After hours:
| Previous Close | 0.7001 |
| Open | 0.7001 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.6800 - 0.7001 |
| 52 Week Range | 0.4500 - 1.4400 |
| Volume | |
| Avg. Volume | 150,746 |
| Market Cap | 35.59M |
| Beta (5Y Monthly) | 1.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5200 |
| Earnings Date | May 23, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.42 |
PR NewswireEvogene Schedules First Quarter 2024 Financial Results Release
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2024, on Thursday, May 23, 2024.
PR NewswireBiomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced that it will present preliminary data from its Phase 1 study of BMC128, in combination with immune checkpoint inhibitor (ICI) immunotherapy, in refractory patients with either non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma (RCC), who previously progressed on immunotherapy, at the American S
- PR Newswire
Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting
Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced that it will present results from pre-clinical studies in its irritable bowel syndrome (IBS) program at the Digestive Disease Week (DDW) 2024 Annual Meeting. The conference is being held in Washington, D.C., May 18-21, 2024.
